Additional Monitoring & Black Triangle
Additional monitoring is a status the EU assigns to medicines whose safety profile is being watched especially closely — typically new products, biologicals, or products with conditions on their authorisation. Medicines under additional monitoring carry an inverted black triangle (▼) in their product information, and the symbol is a deliberate call to action: it tells healthcare professionals and patients that the medicine is under intensified surveillance and that reporting any suspected adverse reaction is particularly valuable. It is one of the few pharmacovigilance mechanisms visible directly to prescribers and patients.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 18 LINKSAdditional monitoring is the EU's intensified-surveillance status: the inverted black triangle (▼) in the product information tells prescribers and patients to report every suspected reaction while the safety profile is still forming.
06 · QUALITY MATURITY — ADDITIONAL MONITORING & BLACK TRIANGLE, REACTIVE TO ADAPTIVE
Additional-monitoring status is not tracked; product information carries the triangle late, wrongly, or not at all.
The triangle is applied at launch, but synchronisation with the evolving EU list is manual and lags status changes.
Product information carries the triangle and statement correctly, and status is tracked so it is added and removed in step with the EU list.
Additional-monitoring status raises PV tempo — weak signals for these products escalate faster and the RMP is visibly more active.
Label, list, and PV system stay reconciled automatically; the status is used to concentrate surveillance where knowledge is thinnest.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 3
Derived from the 3 standards SPEQ maps to this subject, across 3 regulatory bodies: EMA, FDA, ICH.
RECORDS & OBJECTIVE EVIDENCE
- Product information (SmPC and leaflet) carrying the triangle and standard statement
- Tracking of additional-monitoring status against the current EU list
- Change control adding or removing the symbol as status changes
- Records reconciling label state with the published list
- Evidence of elevated pharmacovigilance attention to reports for these products
COMMON INSPECTION FINDINGS
- Triangle absent from product information for a listed product
- Triangle retained after the additional-monitoring period ended
- Product-information label out of step with the current EU list
- Explanatory statement missing or incorrectly worded
- No process to synchronise label state with list updates
What additional monitoring is and why it exists
When a medicine is authorised, its safety profile is characterised mainly from clinical-trial populations — relatively small, selected, and studied for a limited time. Real-world use is larger, more varied, and longer. Additional monitoring is the mechanism for concentrating pharmacovigilance attention on products where the gap between trial knowledge and real-world experience is greatest, so that new or rare risks are detected as quickly as possible after launch.
The status is assigned by the EU on defined grounds: products containing a new active substance, biological medicines including biosimilars, products with a post-authorisation safety study obligation, and products authorised under specific or conditional terms are typical categories under the EU additional-monitoring assignment criteria and legal basis. Assignment is time-bound rather than permanent — a new active substance is typically under additional monitoring for a defined period after authorisation unless there is reason to extend it, the default additional-monitoring duration for new active substances.
The inverted black triangle
The visible marker of additional monitoring is an inverted (point-down) black triangle printed in the summary of product characteristics and the package leaflet, accompanied by a short standard explanatory sentence telling the reader the medicine is subject to additional monitoring and encouraging reporting of suspected adverse reactions. The symbol appears in the product information, not on the outer packaging.
The design intent is behavioural. Spontaneous reporting is the backbone of post-marketing safety, but under-reporting is chronic. The triangle nudges exactly the people who see adverse events — prescribers, pharmacists, patients — to report them for the products where each report carries the most information. SPEQ synthesis: the triangle is less a warning about the medicine’s safety and more a signal about the state of knowledge — it says "we are still learning about this one; your report matters more here."
What it means for the marketing-authorisation holder
For the MAH, additional-monitoring status raises the operational tempo of pharmacovigilance. The product information must carry the triangle and the explanatory statement; the pharmacovigilance system must be alert to the elevated importance of every incoming report; and the status must be tracked so the triangle is added when assigned and removed when the status ends. Getting the presence or absence of the symbol wrong in product information is a compliance error in its own right.
Additional monitoring does not replace the other pharmacovigilance obligations — signal management, periodic safety reporting, the RMP — it intensifies the context in which they operate. A product under additional monitoring is one where a weak signal deserves faster escalation and where the risk-management plan is likely to be more active, because the whole point of the status is that its profile is still being defined.
The additional-monitoring list
The EU maintains a public list of medicines under additional monitoring, updated periodically, so that healthcare professionals and patients can see which products carry the status. The list is a transparency instrument as much as a regulatory one: it makes the surveillance visible and reinforces the reporting message that the triangle carries on individual product information.
Because the status is dynamic — products are added on authorisation and removed when the monitoring period ends or the status is lifted — the list is a moving target, and MAHs must keep their product information synchronised with it. A product that has left the list still bearing a triangle, or one on the list without it, is a discrepancy between the public record and the label that pharmacovigilance governance is expected to catch.
FREQUENTLY ASKED
What does the black triangle (▼) on a medicine mean?
It indicates the medicine is subject to additional monitoring in the EU — its safety is being watched especially closely, typically because it is new, a biological, or authorised under specific conditions. The inverted black triangle in the product information, with an accompanying statement, encourages healthcare professionals and patients to report any suspected adverse reaction.
Which medicines are placed under additional monitoring?
Typically products containing a new active substance, biological medicines including biosimilars, products with a post-authorisation safety study obligation, and products authorised under conditional or specific terms. The status is time-bound rather than permanent and is assigned by the EU, which also maintains a public list of the affected medicines.
Does the black triangle mean a medicine is unsafe?
No. It signals that the medicine is under intensified surveillance and that its safety profile is still being characterised in real-world use, so reporting suspected reactions is particularly valuable. It is a statement about the maturity of safety knowledge, not a warning that the product is dangerous.